Peak Fat astonishingly bullish


Peak fat is here, and Goldman is right to be a buff bull about it. 

The emergence of weight-loss medications, AI-powered drug discovery, genomic and regenerative medicine techniques such as gene and cell therapy, and advances in diagnostics for detection of diseases such as Alzheimer’s imply are markable pace of healthcare innovation that could significantly improve health outcomes and enable people to live better and longer lives.

While the primary goal of healthcare innovation remains raising care quality, these efforts could generate positive spillovers to the macroeconomy as well.

The full text of this article is available to MacroBusiness subscribers

$1 for your first month, then:
Cancel at any time through our billing provider, Stripe
About the author
David Llewellyn-Smith is Chief Strategist at the MB Fund and MB Super. David is the founding publisher and editor of MacroBusiness and was the founding publisher and global economy editor of The Diplomat, the Asia Pacific’s leading geo-politics and economics portal. He is also a former gold trader and economic commentator at The Sydney Morning Herald, The Age, the ABC and Business Spectator. He is the co-author of The Great Crash of 2008 with Ross Garnaut and was the editor of the second Garnaut Climate Change Review.